Voyager Therapeutics Announces Closing of Public Offering of Common Stock
November 10 2017 - 4:05PM
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene
therapy company focused on developing life-changing treatments for
severe neurological diseases, today announced the closing of its
underwritten public offering of 5,175,000 shares of its common
stock at a price of $12.00 per share, before underwriting discounts
and commissions. The shares of common stock issued and sold in the
offering at the closing include 675,000 shares issued upon the
exercise in full by the underwriters of their option to purchase
additional shares at the public offering price, less the
underwriting discounts and commissions. All of the shares in
the offering were sold by Voyager.
The aggregate net proceeds before expenses to
Voyager from the offering are approximately $58.4 million, after
deducting underwriting discounts and commissions.
Morgan Stanley and Cowen acted as joint
book-running managers for the offering. Stifel and Wells Fargo
Securities acted as lead managers for the offering, and Nomura
acted as co-manager.
A shelf registration statement relating to the
shares of common stock offered in the public offering was filed
with the Securities and Exchange Commission (SEC) and was declared
effective on December 20, 2016 (File No. 333-214861). The offering
was made only by means of a prospectus supplement and accompanying
prospectus that form a part of the registration statement. A final
prospectus supplement relating to the offering was filed with the
SEC and is available on the SEC’s website at www.sec.gov. Copies of
the final prospectus supplement and the accompanying prospectus
related to the offering may also be obtained by contacting Morgan
Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick
Street, 2nd Floor, New York, NY 10014 or from Cowen and Company,
LLC, c/o Broadridge Financial Services, Attention: Prospectus
Department, 1155 Long Island Avenue, Edgewood, NY 11717.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene
therapy company focused on developing life-changing treatments for
severe neurological diseases. Voyager is committed to advancing the
field of adeno-associated virus (AAV) gene therapy through
innovation and investment in vector engineering and optimization,
manufacturing and dosing and delivery techniques. Voyager’s
pipeline focuses on severe neurological diseases in need of
effective new therapies, including advanced Parkinson’s disease, a
monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia,
frontotemporal dementia, Alzheimer’s disease and severe, chronic
pain. Voyager has broad strategic collaborations with Sanofi
Genzyme, the specialty care global business unit of Sanofi, and the
University of Massachusetts Medical School. Founded by scientific
and clinical leaders in the fields of AAV gene therapy, expressed
RNA interference and neuroscience, Voyager Therapeutics is
headquartered in Cambridge, Massachusetts.
Forward-Looking Statements
This press release contains forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995 and other federal
securities laws. The use of words such as “may,” “might,” “will,”
“should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,”
“undoubtedly,” “project,” “intend,” “future,” “potential,” or
“continue,” and other similar expressions are intended to identify
forward-looking statements. All forward-looking statements are
based on estimates and assumptions by Voyager’s management that,
although Voyager believes to be reasonable, are inherently
uncertain. All forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially
from those that Voyager expected. Such risks and
uncertainties include, among others, those related to market and
other financing conditions, the initiation and conduct of
preclinical studies and clinical trials, the availability of data
from clinical trials and the expectations for regulatory
submissions and approvals; the continued development of the product
engine; Voyager’s scientific approach and general development
progress; the availability or commercial potential of Voyager’s
product candidates; the sufficiency of cash resources; and need for
additional financing. These statements are also subject to a number
of material risks and uncertainties that are described in Voyager’s
most recent Annual Report on Form 10-K filed with the Securities
and Exchange Commission, as updated by its subsequent filings with
the Securities and Exchange Commission. Any forward-looking
statement speaks only as of the date on which it was made. Voyager
undertakes no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise, except as required by law.
Investor Relations:
Matt Osborne
Vice President of Investor Relations & Corporate Communications
857-259-5353
mosborne@vygr.com
Media:
Katie Engleman
Pure Communications, Inc.
910-509-3977
Katie@purecommunicationsinc.com
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Apr 2023 to Apr 2024